Clinical Trial

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-05
critical Primary endpoint(s) modified 2026-05-14
Trial Details
NCT Number NCT07573111
Lead Sponsor Laguna Biotherapeutics, Inc.
Conditions Acute Leukemia, Myelodysplastic Syndrome
Enrollment 12 participants
Start Date 2026-08
Primary Completion 2028-06 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-04